...antisense oligonucleotide Phase III Topical eye drops Gene Signal International S.A....
...an antisense oligonucleotide Ophthalmic disease Corneal neovascularization Gene Signal International S.A....
...IRS1) mRNA, in Phase III testing by Gene Signal International S.A....

...risk of graft rejection, QOL and complete ophthalmic evaluation scores at day 90 vs. placebo. Gene Signal...
...standard of care (SOC) including corticoids, antiviral and immunosuppressant therapies. Data were published in Ophthalmology. Gene Signal...
...occlusion (CRVO) and Phase II testing to treat wet age-related macular degeneration (AMD). In 2015, Gene Signal...

...Data published in Ophthalmology showed that twice-daily aganirsen ( GS-101 ) eye drops from Gene Signal International S.A. (Lausanne...
...bacterial, viral or traumatic origin in the intent-to-treat (ITT) population of the double-blind, European trial. Gene Signal...

...burning or exudation reported. Data were published in The Journal of Pharmacology and Experimental Therapeutics. Gene Signal...
...Aganirsen has also completed a European Phase III trial to treat neovascular-associated corneal graft rejection. Gene Signal International S.A....

...developing an assay to screen for small molecules that could disrupt the IRS1-mutant p110a interaction. Gene Signal International S.A.'s...

...for life-altering diseases," Ornskov said. Premiplex is the most advanced ROP program in the clinic. Gene Signal International S.A....
...NYSE:AGN), Irvine, Calif. Bausch & Lomb Inc. , Rochester, N.Y. Bayer AG (Xetra:BAYN), Leverkusen, Germany Gene Signal...

...ophthalmic diseases in which neovascularization is an issue, VEGF has become the target of choice. Gene Signal...
...September issue of Ophthalmology showed that 86% of patients undergoing corneal graft who were given Gene Signal's...
...Phase III testing of GS-101 has started and is expected to be completed by 2Q10. Gene Signal...

...mice, a conjugate consisting of a TLR9 agonist and an siRNA targeting the immune suppressor gene signal...

...events. Patients received the drops in 1 eye twice daily. Data were published in Ophthalmology. Gene Signal...